We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, ... Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York. Show more
NEW YORK, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (βIndaptusβ), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral...
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (βIndaptusβ or the βCompanyβ), a clinical stage biotechnology company dedicated to pioneering innovative...
NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (βIndaptusβ or the βCompanyβ), a clinical stage biotechnology company dedicated to pioneering innovative...
NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (βIndaptusβ or the βCompanyβ), a clinical stage biotechnology company dedicated to pioneering innovative...
NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present at two upcoming investor...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.09 | -9 | 1 | 1.02 | 0.8822 | 23093 | 0.93122001 | CS |
4 | -0.14 | -13.3333333333 | 1.05 | 1.0808 | 0.8822 | 20568 | 0.98756819 | CS |
12 | -0.39 | -30 | 1.3 | 2.08 | 0.84 | 117286 | 1.69943266 | CS |
26 | -1.33 | -59.375 | 2.24 | 2.47 | 0.84 | 61794 | 1.69374247 | CS |
52 | -0.99 | -52.1052631579 | 1.9 | 3.1 | 0.84 | 58316 | 1.99018591 | CS |
156 | -5.02 | -84.6543001686 | 5.93 | 7.1 | 0.84 | 82503 | 3.0118889 | CS |
260 | -9.19 | -90.9900990099 | 10.1 | 28.8299 | 0.84 | 386391 | 9.10267828 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions